Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish
Fourth-quarter loss per share came in at $0.16, lower than the $0.24 in the corresponding period of 2023, and below the consensus estimate of $0.25, according to FinChat data.